Vor Biopharma
VOR • NASDAQ
Vor Biopharma is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Jean-Paul Kress, with a market cap of $308.1M.
CEOJean-Paul Kress
Market Cap$308.1M
Biotechnology
Healthcare
Employees168.0
Websitevorbio.com
Country
United States of America
Next Earnings
Upcoming earnings announcement for Vor Biopharma
Date
Thursday, March 19, 2026 (in 2 months)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q4 2025
EPS Estimate
-$1.31
Earnings History
Past 12 earnings reports for Vor Biopharma
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Nov 13, 2025 | Q3 2025 | -$3.33Est: -$3.68 | +9.5% | - | — |  10-Q |
| Aug 12, 2025 | Q2 2025 | -$2.19Est: -$0.58 | -277.6% | - | — | 10-Q |
| May 14, 2025 | Q1 2025 | -$0.26Est: -$0.25 | -4.0% | - | — | 10-Q |
| Mar 20, 2025 | Q4 2024 | -$0.44Est: -$0.31 | -41.9% | - | — | 10-K |
| Nov 7, 2024 | Q3 2024 | -$0.40Est: -$0.40 | 0.0% | - | — | 10-Q |
| Aug 8, 2024 | Q2 2024 | -$0.41Est: -$0.42 | +2.4% | - | — | 10-Q |
| May 9, 2024 | Q1 2024 | -$0.45Est: -$0.48 | +6.2% | - | — | 10-Q |
| Mar 20, 2024 | Q4 2023 | -$0.39Est: -$0.50 | +22.0% | - | — | 10-K |
| Nov 7, 2023 | Q3 2023 | -$0.49Est: -$0.47 | -4.3% | - | — | — |
| Aug 10, 2023 | Q2 2023 | -$0.45 | — | - | — | 10-Q |
| May 11, 2023 | Q1 2023 | -$0.43Est: -$0.38 | -13.2% | - | — | — |
| Mar 23, 2023 | Q4 2022 | -$0.53Est: -$0.60 | +11.7% | - | — | — |